Grant Awarded to Test Effect of Tibetan Yoga on Women With Breast Cancer

Publication
Article
OncologyONCOLOGY Vol 20 No 9
Volume 20
Issue 9

Researchers at The University of Texas M. D. Anderson Cancer Center, Houston, have received a $2.4 million grant from the National Cancer Institute to study the effects of Tibetan yoga in women with breast cancer who are undergoing chemotherapy.

Researchers at The University of Texas M. D. Anderson Cancer Center, Houston, have received a $2.4 million grant from the National Cancer Institute to study the effects of Tibetan yoga in women with breast cancer who are undergoing chemotherapy.

The award is the largest ever made to study Tibetan yoga in cancer patients, say the researchers, who published a 2004 study in

Cancer

that found the practice led to significant sleep improvements in patients with lymphoma. Another small study of Tibetan yoga also found improvements in cancer-related symptoms and intrusive thoughts in women with breast cancer.

Rationale for Trial

With this grant support, the research team will conduct a large randomized trial that will compare Tibetan yoga vs simple stretching or usual care in women who will be undergoing chemotherapy to treat their breast cancer. Dr. Lorenzo Cohen, an associate professor in the departments of behavioral science and palliative care and rehabilitation medicine, and the director of the Integrative Medicine Program at M. D. Anderson is the study's principal investigator.

Most of what is known about yoga in the West comes from the Indian tradition, but Cohen has chosen to study yogic practices from Tibet. His team was the first to design pilot studies that examined the benefits of these techniques to cancer patients.

"Cancer and its treatment are associated with considerable distress, impaired quality of life, poor mental health, and reduced physical function. This is particularly true for women with breast cancer who receive multimodality treatment over an extended period of time," he says. "For thousands of years, Tibetans have been employing a form of yoga that we think could help ameliorate the treatment-related morbidity that accumulates over time in cancer patients."

Study Protocol

In the newly funded study, women with breast cancer who are scheduled to undergo chemotherapy will be randomly assigned to either a Tibetan yoga group, a control group that does simple stretching, or to a group that receives standard care. The participants will practice their assigned techniques for 7 weeks during chemotherapy, and then will have five booster sessions over the next 6 months.

The study will assess the physical and psychological benefits of the yoga program, and will specifically examine such patient lifestyle factors as fatigue and sleep, mental health, and distress. Additionally, the study will evaluate cognitive and emotional processing, social networking and interactions, coping and other psychosocial factors, Cohen says.

Possible Health Benefits?

Although the study is designed to look at improvements in quality of life, it could be that Tibetan yoga offers health benefits as well, Cohen says.

"Theoretically, if the Tibetan yoga intervention is found to decrease the patient's stress level, it could have an impact on their immune system," Cohen says. "There is extensive evidence showing that stress suppresses cell-mediated immunity, a component of the immune system involved in tumor surveillance. Tibetan yoga also might have an impact on patients' hormonal activity."

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.